Overview An Extension Study of JR-141 in Patients With Mucopolysaccharidosis II Status: Active, not recruiting Trial end date: 2030-03-31 Target enrollment: Participant gender: Summary Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II. Phase: Phase 2/Phase 3 Details Lead Sponsor: JCR Pharmaceuticals Co., Ltd.